Boston Scientific cyberattack puts 2026 guidance at risk as recovery remains uncertain

The incident is no longer just an operational disruption; it is now a guidance event. Boston Scientific says the cyberattack is likely to have a material impact on both third-quarter and full-year 2026 results, meaning the market's standing assumption of achieving the guidance issued on July 29 is no longer intact. 〔0〕

The recovery is progressing, but not fast enough to preserve the prior outlook. Major distribution centers are processing orders at or above normal levels, sterilization facilities are operating, and manufacturing has resumed across most global facilities. Those improvements limit the downside versus a prolonged shutdown, but management still says the timeline for full recovery is uncertain and that some lost revenue may only be recovered later. 〔1〕

The key miss is that both sales growth and adjusted EPS guidance are now unlikely to hold. The filing does not provide replacement ranges, so the size of the financial shortfall remains unresolved rather than fully quantified. That uncertainty is itself negative: investors must wait until October 28 for a revised outlook, while also assessing possible backlog recovery, execution costs and any further operational or legal fallout.

The net read is a clear guidance cut, despite substantial system restoration. The cyber incident was already disclosed on August 26, so the attack itself is partly known; the new information is the explicit admission that its financial impact is likely material and that prior 2026 targets are no longer credible. 〔2〕